Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Supports Roche HPV Assay To Replace Pap As Primary Cervical Cancer Screen

This article was originally published in The Gray Sheet

Executive Summary

The Microbiology Devices Panel provided unanimous support Roche’s submission to upgrade labeling for it cobas HPV test as a first-line, primary screen for cervical cancer.

You may also be interested in...

Roche’s HPV Test Approved As First-Line Cervical Cancer Screen

The firm’s cobas human papillomavirus test is the first to gain approved labeling as a primary screen. It could be a market advantage for Roche, but the company now needs to work with clinical guideline developers to put the approved indication into routine practice.

HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines

The U.S. Preventive Services Task Force finds the evidence inconclusive for employing human papillomavirus testing as part of cervical cancer screening for women over 30, and it explicitly recommends against HPV testing in younger women.

Roche Ramps Up Sales Force For U.S. Launch Of HPV Test

Roche has been hiring additional sales reps and training its existing sales force in preparation for the U.S. launch of its cobas HPV test to identify women at high risk of developing cervical cancer.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts